Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial shows reduced kidney failure and cardiovascular events in type 2 diabetes with nephropathy, indicating potential treatment benefits.
Key Points
- This research aims to evaluate the effects of canagliflozin on renal outcomes in patients with type 2 diabetes and nephropathy.
- Randomized trial design with placebo control
- Patients with type 2 diabetes and kidney disease
- Median follow-up of 2.62 years
- Lower risk of kidney failure in the canagliflozin group compared to placebo
- Reduced incidence of cardiovascular events in the canagliflozin group
- Statistical significance not detailed in the abstract
Cite This Study
Perkovic et al. (2019) studied this question.